血液科

订阅

MedSci主页 / 所有栏目 / 血液科

Leukemia Res：阿那格雷在真性红细胞增多症中用于血小板定向细胞减少：从大型多中心数据库中洞察实用性和安全性结果

2022-09-11 将军的九分裤 MedSci原创

真性红细胞增多症阿那格雷血小板定向细胞减少
关注

阿那格雷 (ANA) 是一种血小板特异性细胞减少剂，多用于高危原发性血小板增多症的指南指导管理。尽管耐受性有限，ANA仍是 PV 患者选择性血小板控制的有效选择

阿那格雷 (ANA) 是一种血小板特异性细胞减少剂，多用于高危原发性血小板增多症的指南指导管理。在真性红细胞增多症 (PV) 的背景下，ANA 偶尔用于临床实践，虽然不是指南指导的 PV 治疗的一部分，但 ANA 经常在临床实践中用作血小板降低剂，用于治疗伴有血小板增多症的 PV 患者。然而，这种方法的安全性和有效性尚未得到正式研究。此次报道的研究的目的是利用一个完善的、大型、多中心的 PV 患者数据库来回顾性描述接受 ANA 治疗的患者的特征和结果。

研究利用了来自美国 10 家机构的 527 名PV患者的既定数据库。对于初始数据库纳入，患者必须已被诊断为 2016 年世界卫生组织 (WHO) 标准所定义的 PV，并且已年满 18 岁。在 527 名 PV 患者的多中心队列中，48 名接受了 ANA（9 名因缺乏数据而被排除）。27 人 (69.2%) 有高危 PV，10 人 (25.6%) 曾有血栓形成，没有人有严重的血小板增多症、获得性血管性血友病和/或对羟基脲的耐药性。

图1：流程图

图 2：阿那格雷停药时间的 Kaplan-Meier 曲线。

虽然 ANA 有效地降低了中位血小板计数，但 43。5% 的患者在 ANA 停药时有未解决的血小板增多症。治疗中出现的不良事件——包括头痛、心悸和心律失常、恶心、呕吐和/或腹泻——导致 76.9% 的患者停用 ANA。此外，三名患者在 ANA 治疗的中位持续时间为 27.5 个月期间经历了动脉血栓形成。

表：导致ANA剂量减少或停用的诱发事件。

总体而言，目前的研究表明，尽管耐受性有限，ANA仍是 PV 患者选择性血小板控制的有效选择。在接受 ANA 治疗的 PV 患者队列中，血栓并发症（7.7%）和因毒性而停止治疗的发生率（76.9%）值得注意。目前的数据表明，将血小板目标作为 PV 的治疗终点缺乏明确的益处，相反，PV患者可以通过持续使用低剂量阿司匹林来降低血栓风险，从而靶使PV相关的血栓烷生物合成增加。在评估 ANA 在 PV 中的作用的大型前瞻性研究之前，研究人员建议考虑到伴有出血风险和症状性血小板增多症的 PV 患者，可使用血小板定向细胞减灭术。即使在这些情况下，他们也提倡使用非选择性细胞减灭剂，例如 HU 和 IFN-α。

 

原始出处：

Rippel N, Tremblay D, Zubizarreta N, Podoltsev N, Gotlib J, Heaney M, Kuykendall A, O'Connell C, Shammo JM, Fleischman A, Kremyanskaya M, Hoffman R, Mesa R, Yacoub A, Mascarenhas J. Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database. Leuk Res. 2022 Aug;119:106903. doi: 10.1016/j.leukres.2022.106903. Epub 2022 Jun 16. PMID: 35717689.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1904148, encodeId=618a19041488b, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Dec 06 00:46:37 CST 2022, time=2022-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069710, encodeId=ec1e2069e101b, content=<a href='/topic/show?id=ebbc4606222' target=_blank style='color:#2F92EE;'>#实用性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46062, encryptionId=ebbc4606222, topicName=实用性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue May 16 20:46:37 CST 2023, time=2023-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769090, encodeId=b4211e690907d, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Fri Mar 31 09:46:37 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282115, encodeId=102c1282115ec, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Sep 12 05:46:37 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555476, encodeId=149015554e673, content=<a href='/topic/show?id=f016e71581b' target=_blank style='color:#2F92EE;'>#红细胞增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77158, encryptionId=f016e71581b, topicName=红细胞增多症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a1014606284, createdName=linlin2317, createdTime=Mon Sep 12 05:46:37 CST 2022, time=2022-09-12, status=1, ipAttribution=)]
    2022-12-06 heli0118

    #多中心#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1904148, encodeId=618a19041488b, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Dec 06 00:46:37 CST 2022, time=2022-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069710, encodeId=ec1e2069e101b, content=<a href='/topic/show?id=ebbc4606222' target=_blank style='color:#2F92EE;'>#实用性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46062, encryptionId=ebbc4606222, topicName=实用性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue May 16 20:46:37 CST 2023, time=2023-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769090, encodeId=b4211e690907d, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Fri Mar 31 09:46:37 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282115, encodeId=102c1282115ec, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Sep 12 05:46:37 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555476, encodeId=149015554e673, content=<a href='/topic/show?id=f016e71581b' target=_blank style='color:#2F92EE;'>#红细胞增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77158, encryptionId=f016e71581b, topicName=红细胞增多症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a1014606284, createdName=linlin2317, createdTime=Mon Sep 12 05:46:37 CST 2022, time=2022-09-12, status=1, ipAttribution=)]
    2023-05-16 lidong40

    #实用性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1904148, encodeId=618a19041488b, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Dec 06 00:46:37 CST 2022, time=2022-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069710, encodeId=ec1e2069e101b, content=<a href='/topic/show?id=ebbc4606222' target=_blank style='color:#2F92EE;'>#实用性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46062, encryptionId=ebbc4606222, topicName=实用性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue May 16 20:46:37 CST 2023, time=2023-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769090, encodeId=b4211e690907d, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Fri Mar 31 09:46:37 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282115, encodeId=102c1282115ec, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Sep 12 05:46:37 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555476, encodeId=149015554e673, content=<a href='/topic/show?id=f016e71581b' target=_blank style='color:#2F92EE;'>#红细胞增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77158, encryptionId=f016e71581b, topicName=红细胞增多症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a1014606284, createdName=linlin2317, createdTime=Mon Sep 12 05:46:37 CST 2022, time=2022-09-12, status=1, ipAttribution=)]
    2023-03-31 liao1632

    #定向#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1904148, encodeId=618a19041488b, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Dec 06 00:46:37 CST 2022, time=2022-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069710, encodeId=ec1e2069e101b, content=<a href='/topic/show?id=ebbc4606222' target=_blank style='color:#2F92EE;'>#实用性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46062, encryptionId=ebbc4606222, topicName=实用性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue May 16 20:46:37 CST 2023, time=2023-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769090, encodeId=b4211e690907d, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Fri Mar 31 09:46:37 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282115, encodeId=102c1282115ec, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Sep 12 05:46:37 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555476, encodeId=149015554e673, content=<a href='/topic/show?id=f016e71581b' target=_blank style='color:#2F92EE;'>#红细胞增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77158, encryptionId=f016e71581b, topicName=红细胞增多症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a1014606284, createdName=linlin2317, createdTime=Mon Sep 12 05:46:37 CST 2022, time=2022-09-12, status=1, ipAttribution=)]
    2022-09-12 kord1982

    #红细胞#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1904148, encodeId=618a19041488b, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Dec 06 00:46:37 CST 2022, time=2022-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069710, encodeId=ec1e2069e101b, content=<a href='/topic/show?id=ebbc4606222' target=_blank style='color:#2F92EE;'>#实用性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46062, encryptionId=ebbc4606222, topicName=实用性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue May 16 20:46:37 CST 2023, time=2023-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769090, encodeId=b4211e690907d, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Fri Mar 31 09:46:37 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282115, encodeId=102c1282115ec, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Sep 12 05:46:37 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555476, encodeId=149015554e673, content=<a href='/topic/show?id=f016e71581b' target=_blank style='color:#2F92EE;'>#红细胞增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77158, encryptionId=f016e71581b, topicName=红细胞增多症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a1014606284, createdName=linlin2317, createdTime=Mon Sep 12 05:46:37 CST 2022, time=2022-09-12, status=1, ipAttribution=)]
    2022-09-12 linlin2317

    #红细胞增多症#

    0

相关资讯

Blood：JAK2ex13InDel驱动成瘤转化，与慢性嗜酸性粒细胞白血病和真性红细胞增多症有关

中心点：一种新的JAK2插入/缺失突变与嗜酸性粒细胞增多症和红细胞增多症有关，可能代表了一种新的临床实体。JAK2ex13InDel可在配体缺乏的情况下，通过β常见链受体导致组成性激活促进信号转导激活。摘要：Janus激酶2（JAK2）的JH2结构域的V617F突变是几种骨髓增值性肿瘤（MPNs）的致癌驱动突变，包括原发性血小板减少症、骨髓纤维化和真性红细胞增多（PV）。在MPNs中，还检测到JA

Blood：真性红细胞增多症患者白细胞持续升高预示高疾病进展风险

中心点：白细胞持续升高可预示真性红细胞增多症病程进展。没有检验指标可预测血栓形成。摘要：关于真性红细胞增多症(PV)中持续性白细胞增多与血栓形成风险和疾病演变之间的关系，仍有许多未解决的问题，因为关于该问题的许多已发表的文献并没有适当地利用重复测量的数据或时间依赖性模型来回答这些问题。为了解决这一知识缺口，Ronner等人分析了美国10个学术机构的520位PV患者的回顾性数据库。在随访期间，每间隔

Lancet haematol：Ropeginterferon alfa-2b对比羟基脲用于真性红细胞增多症的长期疗效！

PROUD-PV和CONTINUATION-PV试验旨在比较新型长效型单修饰脯氨酸干扰素Ropeginterferon alfa-2b和羟基脲（真性红细胞增多症的标准治疗方案）的疗效，治疗时间超过3年。PROUD-PV及其拓展研究，CONTINUATION-PV，是一项在欧洲48个诊所开展的随机化对照的开放性的3期试验，招募年满18岁的真性红细胞增多症早期患者（无细胞减少术治疗史或羟基脲治疗短于3

关注罕见病“真性红细胞增多症”：PTG-300获美国FDA孤儿药物认定

真性红细胞增多症（polycythemia vera, PV）是一种骨髓增殖性肿瘤，骨髓增殖性肿瘤是一组源于造血干细胞、以形态学成熟度不一的骨髓细胞克隆增殖为特征的恶性肿瘤。

Blood：羟基脲 vs 聚乙二醇化IFN-α 治疗原发性血小板增多症/真性红细胞增多症

羟基脲和聚乙二醇化 IFN-α 都可以有效治疗原发性血小板增多症和真性红细胞增多症

Lancet Haematol：鲁索替尼治疗真性红细胞增多症的5年随访结果

鲁索替尼可作为无脾肿大的控制欠佳的真性红细胞增多症患者的二线治疗选择